Intra-individual Real Life Effects of Cocoa Flavanols on Blood Pressure and Arterial Stiffness

Sponsor
University of Surrey (Other)
Overall Status
Completed
CT.gov ID
NCT05446818
Collaborator
(none)
12
1
2
21.4
0.6

Study Details

Study Description

Brief Summary

Very controlled dietary intervention studies support that individual polyphenol rich foods and isolated polyphenols can increase endothelial function and HDL cholesterol and decrease blood pressure, arterial stiffness, and LDL cholesterol even in healthy subjects. The intake of (-)-epicatechin, the major polyphenol in cocoa, was previously mechanistically linked with acute improvements in endothelial function and nitric oxide availability. A profound understanding of inter- and intra-individual variability of responses in real life are an important area of research in a world that aims at personalized nutrition and medicine. N-of-1 trials are a powerful tool allowing to study small effects even in fewer subjects and help account for intra-individual variations in responses. The overall aim of the present pilot study is to evaluate intra-and inter-individual variability of responses to cocoa flavanols in everyday life using the N-of-1 paradigm. In this pilot study, young healthy humans will monitor blood pressure, pulse wave velocity, heart rate, diet, and physical activity on 8 days using a personal and wearable devices. Each subject will undergo the 8 study days; 4 days with cocoa flavanol capsules (CF; containing 750 mg (1500 mg per day)) and 4 days with calorically matched placebo capsules (P; 0 mg cocoa flavanols) taken at the same time in the morning with breakfast and at night before going to bed. The subjects will be randomized to different treatment allocation sequences to allow blinding of volunteers and investigator; either CF-P-CF-P-CF-P-CF-P or P-CF-P-CF-P-CF-P-CF.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Cocoa flavanol (CF)
  • Other: Placebo (P)
N/A

Detailed Description

Background: Very controlled dietary intervention studies support that individual polyphenol rich foods and isolated polyphenols can increase endothelial function and HDL cholesterol and decrease blood pressure, arterial stiffness, and LDL cholesterol even in healthy subjects. The intake of (-)-epicatechin, the major polyphenol in cocoa, was previously mechanistically linked with acute improvements in endothelial function and nitric oxide availability. However, the clinical intervention studies were performed in tightly controlled experimental settings and variability of individual responses were not investigated. A profound understanding of inter- and intra-individual variability of responses in real life are an important area of research in a world that aims at personalized nutrition and medicine. N-of-1 trials are a powerful tool allowing to study small effects even in fewer subjects and help account for intra-individual variations in responses. N-of-1 trials in clinical medicine are multiple crossover trials, usually randomized and often blinded, conducted in a single patient.

Aim, hypothesis, objectives: The overall aim of the present pilot study is to evaluate intra-and inter-individual variability of responses to cocoa flavanols in everyday life using the N-of-1 paradigm. It is the hypothesis that cocoa flavanols decrease blood pressure and arterial stiffness in everyday life of healthy individuals. The objectives to investigate the aim are (1) to test the effect of CF using wearable devices repeatedly measuring blood pressure, arterial stiffness, and heart rate in healthy individuals participating in in every days life, (2) to explore intra-and inter-individual variability in responses by repeatedly testing responses in the same individuals, and (3) to test different statistical models taking repeated measurements in the same subject into account.

Methods: In this pilot study, young healthy humans will monitor blood pressure, pulse wave velocity, heart rate, diet, and physical activity on 8 days using a personal and wearable devices. Each subject will undergo the 8 study days; 4 days with cocoa flavanol capsules (CF; containing 750 mg (1500 mg per day)) and 4 days with calorically matched placebo capsules (P; 0 mg cocoa flavanols) taken at the same time in the morning with breakfast and at night before going to bed. The subjects will be randomized to different treatment allocation sequences to allow blinding of volunteers and investigator; either CF-P-CF-P-CF-P-CF-P or P-CF-P-CF-P-CF-P-CF. Blood pressure and heart rate will be measured by a standard upper arm blood pressure cuff and estimated by a fitness wristband and pulse wave velocity via a finger device in 30 min intervals for 3 h starting after morning treatment ingestion followed by hourly intervals until going to bed.

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Series of Repeated Cross-over Randomized Controlled Double-blind N-of-1 Pilot Studies; each subject receives 4 times treatment and 4 times placeboSeries of Repeated Cross-over Randomized Controlled Double-blind N-of-1 Pilot Studies; each subject receives 4 times treatment and 4 times placebo
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Intervention and placebo in same number and size of capsules
Primary Purpose:
Basic Science
Official Title:
Intra-individual Real Life Effects of Cocoa Flavanols on Blood Pressure and Arterial Stiffness Using Personal Devices in Healthy Humans: Series of Repeated Cross-over Randomized Controlled Double-blind N-of-1 Pilot Studies
Actual Study Start Date :
Apr 22, 2019
Actual Primary Completion Date :
Feb 1, 2021
Actual Study Completion Date :
Feb 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Flavanol first

Subjects will receive over 8 days both cocoa flavanols (CF) and placebo (P) capsules on alternating days. Sequence of this arm is: CF-P-CF-P-CF-P-CF-P

Dietary Supplement: Cocoa flavanol (CF)
2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)

Other: Placebo (P)
2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)

Active Comparator: Placebo first

Subjects will receive over 8 days both cocoa flavanols (CF) and placebo (P) capsules on alternating days. Sequence of this arm is: P-CF-P-CF-P-CF-P-CF

Dietary Supplement: Cocoa flavanol (CF)
2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)

Other: Placebo (P)
2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)

Outcome Measures

Primary Outcome Measures

  1. Change in systolic and diastolic blood pressure [Measurements over 24 hours]

    Standard upper arm cuff (day) and wrist band (day and night)

  2. Change in arterial stiffness [Measurements over 24 hours]

    Pulse wave velocity by finger clip (iHeart)

  3. Change in heart rate [Measurements over 24 hours]

    Fitness bracelet

Secondary Outcome Measures

  1. Physical activity [Assessed over 24 hours]

    Steps measured on fitness bracelet

Other Outcome Measures

  1. Dietary composition [Assessed over 24 hours]

    Dietary assessment based on food diary

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy

  • Body mass index <30 kg/m2

  • Age <45 years

Exclusion Criteria:
  • Diabetes mellitus

  • Symptoms of acute infection

  • Cardiac arrhythmia

  • Active malignancy

  • Clinical signs or symptoms of cardiovascular disease including:

  1. Angina pectoris

  2. Shortness of breath

  3. Palpitations

  4. Syncopes

  5. Claudication

  • Active vasoactive medication

  • Vitamin supplements.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Surrey Guildford United Kingdom GU2 7XH

Sponsors and Collaborators

  • University of Surrey

Investigators

  • Principal Investigator: Christian Heiss, MD, University of Surrey

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Surrey
ClinicalTrials.gov Identifier:
NCT05446818
Other Study ID Numbers:
  • FER-1819-040
First Posted:
Jul 7, 2022
Last Update Posted:
Jul 7, 2022
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jul 7, 2022